Vaxcyte 将来の成長

Future 基準チェック /06

Vaxcyteの収益は年間4.5%で減少すると予測されていますが、年間収益は年間89.1%で増加すると予想されています。EPS は年間2.2%で減少すると予想されています。

主要情報

-4.5%

収益成長率

-2.2%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	89.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	06 Nov 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Dec 22

Vaxcyte appoints new CBO, CMO

Oct 11

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Aug 05

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

業績と収益の成長予測

NasdaqGS:PCVX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	21	-654	-516	-820	7
12/31/2025	N/A	-608	-544	-543	8
12/31/2024	N/A	-486	-509	-331	8
9/30/2024	N/A	-508	-616	-470	N/A
6/30/2024	N/A	-497	-582	-467	N/A
3/31/2024	N/A	-437	-483	-408	N/A
12/31/2023	N/A	-402	-365	-297	N/A
9/30/2023	N/A	-300	-245	-233	N/A
6/30/2023	N/A	-265	-220	-214	N/A
3/31/2023	N/A	-245	-199	-191	N/A
12/31/2022	N/A	-223	-176	-171	N/A
9/30/2022	N/A	-174	-163	-156	N/A
6/30/2022	N/A	-143	-153	-146	N/A
3/31/2022	N/A	-118	-144	-136	N/A
12/31/2021	N/A	-100	-128	-121	N/A
9/30/2021	N/A	-92	-87	-81	N/A
6/30/2021	N/A	-87	-70	-66	N/A
3/31/2021	N/A	-83	-48	-46	N/A
12/31/2020	N/A	-89	-48	-47	N/A
9/30/2020	N/A	-83	-52	-50	N/A
6/30/2020	N/A	-73	-48	-47	N/A
3/31/2020	N/A	-64	-53	-51	N/A
12/31/2019	N/A	-50	-48	-47	N/A
12/31/2018	N/A	-29	-32	-30	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PCVX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PCVX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PCVX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PCVX来年は収益がないと予測されています。

高い収益成長: PCVX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PCVXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Vaxcyte 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 27% to US$131

Price target increased by 7.8% to US$71.14

Price target increased to US$60.50

Price target increased to US$56.00

Recent updates

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Co-Founder notifies of intention to sell stock

Insufficient new directors

President & CFO notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

Executive VP & COO notifies of intention to sell stock

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Price target increased by 27% to US$131

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

President & CFO notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte Appoints John Furey to Board of Directors

President & CFO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

President & CFO notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Price target increased by 7.8% to US$71.14

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Co-Founder notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Senior VP notifies of intention to sell stock

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

President & CFO notifies of intention to sell stock

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Co-Founder notifies of intention to sell stock

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

President exercised options to buy US$1.1m worth of stock.

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Executive VP & COO exercised options to buy US$5.1m worth of stock.

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

Independent Director exercised options and sold US$131k worth of stock

High number of new directors

Price target increased to US$60.50

Independent Director exercised options and sold US$147k worth of stock

Price target increased to US$56.00

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte appoints new CBO, CMO

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs